natgillin/translations-raw huggingface dataset:
the same X-ray powder diffraction (XRPD) pattern as a) or b) post storage at 25°C and 92% RH for 12 days. 
isti spektar difrakcije X-zraka praha (XRPD) kao što su (a) ili (b), poslije 12 dana skladištenja na 25°C i 92% RH.
The blister pack according to Claim 16, in which said layer of polymer material (8A) is between 5 and 50 µm thick. 
Blister pakiranje prema 14. zahtjevu, naznačeno time da navedeni polimerski materijal (8a) debeo između 5 1 50 um.
motorization means (3) operatively connected with said support shaft (2) in order to rotate it around said longitudinal axis (Y); 
motorizacijska sredstva (3) operativno povezane s potpoprnom osovinom (2) kako bi se rotirala oko navedene longitudinalne osi (Y);
determining whether the guest operating system voluntarily exited prior to expiration of the grace period; based on determining the guest operating system voluntarily exited prior to expiration of the grace period, providing to the guest operating system, a next time the guest operating system executes, positive feedback indicating voluntarily exiting prior to expiration of the grace period; and based on determining the guest operating system is tardy on voluntarily exiting prior to expiration of the grace period, providing to the guest operating system, a next time the guest operating system executes, an exception feedback indication indicating tardiness in voluntarily exiting. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što postupak dodatno uključuje: određivanje je li gostujući operativni sustav izašao dobrovoljno prije isteka razdoblja počeka; na osnovi određivanja da je gostujući operativni sustav izašao dobrovoljno prije isteka razdoblja počeka, osiguravanje gostujućem operativnom sustavu, sljedeći put gostujući operativni sustav izvršava, pozitivna povratna veza koja ukazuje na dobrovoljni izlaz prije isteka razdoblja počeka; i na osnovi određivanja da gostujući operativni sustav kasni kod dobrovoljnog izlaza prije isteka razdoblja počeka, osiguravanje gostujućem operativnom sustavu, sljedeći put gostujući operativni sustav izvršava, povratna indikacija o izuzeću koja ukazuje na kašnjenje kod dobrovoljnog izlaza.
The pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1 -hydroxynaphthalene-2- carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate and benzenesulfonate. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što se farmaceutski prihvatljiva sol glikopirolata bira između fluorida, klorida, bromida, jodida, nitrat, sulfata, fosfata, formijata, acetata, trifluoracetata, propionata, butirat, laktata, citrata, tartarata, malata, maleata, sukcinata, benzoata, p-klorbenzoata, difenilacetata ili trifenilacetata, o-hidroksibenzoata, p-hidroksibenzoata, 1-hidroksinaftalen-2-karboksilata, 3-hidroksinaftalen-2-karboksilata, metansulfonata i benzensulfonata.
The peptide according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid za upotrebu u skladu s patentnim zahtjevom 1, pri čemu se navedeni fuzijski protein sastoji od N-terminalnih aminokiselina HLA-DR invarijantnog lanca vezanog za antigene (Ii).
X is optionally substituted aryl; 
X je opcionalno supstituirani aril;
The compound according to formula (10), or salt thereof, is subjected to ring-closing conditions to obtain a compound according to formula (1) or salt thereof. Suitable ring closing conditions are those that employ a base. 
e) reakcija spoja prema formuli (10) ili njegove soli, pri čemu RS je vodik ili alkil, pod uvjetima zatvaranja prstena, kako bi se dobio spoj u skladu s formulom (1) ili njegova sol.
Thus, for example, for intravenous administration, a dose in the range, for example, 0.1 mg/kg to 30 mg/kg body weight will generally be used. 
Stoga će, na primjer, za intravenozno davanje obično biti korištena doza u rasponu od, na primjer, 0.1 mg/kg do 30 mg/kg tjelesne težine.
The method according to claim 16, wherein the image pattern comprises a matrix of images spaced at a first mutual distance D, and the array of lenses (11, 12; 17, 18) is comprised of lens elements that are spaced apart from each other at a second mutual distance L which differs from the first mutual distance D. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 9-11, naznačen time što se uzorak slike (5,6) sastoji od matrice slika razmaknutih na uzajamnoj udaljenosti D, gdje polje leća (11,12;17,18) sadrži lećne elemente koji su međusobno razmaknuti na uzajamnoj udaljenosti L različitoj od D.
and R2 is a substituted or unsubstituted phenyl. 
ž i R? je supstituiran ili nesupstituiran fenil.
pressure sealing the chamber; and providing heat to the substance to heat the substance to a temperature in the range of 150-400 degrees Celsius to thermally decompose the sodium bicarbonate to release carbon dioxide. 
brtvljenje tlačne komore pod tlakom (21; 204; 304); i zagrijavanje navedene komore na temperaturu u rasponu od 150 - 400 stupnjeva Celzija da se oslobodi ugljični dioksid iz navedenog natrij bikarbonata, gdje je natrijev bikarbonat u barem jednom obliku:
The pharmaceutical composition according to any of claims 14 to 19, further comprising at least one suitable adjuvant. 
Farmaceutski sastav sukladno bilo kojoj od tvrdnji 10 do 14, nadalje sadrži barem jedno prikladno pomoćno sredstvo.
Use according to claim 14 wherein said excipient is selected from the group consisting of: ionizing agents; antioxidant agents; chelating agents; moisturizing agents; thermoviscosizing agents; decongestant agents; disinfectant and/or antimicrobial agents; flavouring and colorants. 
Upotreba u skladu s patentnim zahtjevom 14, naznačena time što navedenu pomoćnu tvar se bira iz skupine koju čine: ionizacijska sredstva; antioksidansi; kelirajuća sredstva; ovlaživači; termoviskozirajuća sredstva; dekongestivi; dezinficijensi i/ili antimikrobna sredstva; arome i boje. t>&
A biomass pyrolysis apparatus according to claim 5, further having an air and/or water inlet for introducing air and/or water into the second conveying means for reaction with the char conveyed by the second conveying means. 
Uređaj za pirolizu biomase prema zahtjevu 8 ili 9, naznačen time, da ima ulazni otvor za vodu i/ili zrak (28) za uvođenje zraka i/ili vode u drugo transportno sredstvo (18, 80) za reakciju s ugljenom koji se transportira putem drugog transportnog sredstva (18, 80).
The method for cleaning an air conditioner indoor unit and outdoor unit according to claim 6, characterized in that, wherein the water volume m is calculated according to the following formula: EPMATHMARKEREP wherein L is a length of a radiator heatsink, W is a width of the radiator heatsink, H is a height of the radiator heatsink, n is a quantity of the radiator heatsink, h1 is a thickness of the water film, k1 is a margin constant, and p is a density of water. 
Postupak za čišćenje unutarnje jedinice i vanjske jedinice klima uređaja u skladu sa patentnim zahtjevom 6, naznačen time što, se volumen vode m izračunava prema sljedećoj formuli: [image] pri čemu je L duljina hladnjaka radijatora, W je širina hladnjaka radijatora, H je visina hladnjaka radijatora, n je količina hladnjaka radijatora, h1 je debljina vodenog filma, k1 je rub konstante, a p je gustoća vode.
A method according to any of the preceding claims, wherein said organic material is selected from the group consisting of sludge, such as sewage sludge, liquid manure, corn silage, clarifier sludge, black liquor, residues from fermentation, residues from juice production, residues from edible oil production, residues from fruit and vegetable processing, residues from food and drink production, leachate or seepage water or a combination thereof. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je navedeni organski materijal odabran iz grupe koja se sastoji od taloga, kao što je sanitarni talog, tekuće gnojivo, kukuruzna silaža, talog od bistrenja, crni liker, ostaci od fermentacije, ostaci od proizvodnje soka, ostaci od proizvodnje jestivog ulja, ostaci od obrade voća 1 povrća, ostaci od proizvodnje hrane 1 pića, eluat ili cijeđena voda ili njihova kombinacija.
A surfactant product according to claim 1, wherein the second effervescent composition comprises sodium bicarbonate in an amount of 40 to 75 wt % based on the second effervescent composition. 
Proizvod površinski aktivne tvari prema bilo kojem od zahtjeva 1 do 4 naznačen time da drugi pjenušavi materijal sadrži natrijev bikarbonat u količini od 40 do 75 tež.% bazirano na drugom pjenušavom materijalu.
an insertion tube (6) having a first end and a second end, being arranged in connection with the handle and the first end of the insertion tube (6) comprising at least one frame stot (21) adapted to receive a frame (1a) of the intrauterine system, 
- < cjevčicu za umetanje (6) koja ima prvi i drugi kraj, povezana je sa držačem i prvi kraj cjevčice za umetanje (6) obuhvaća barem jedno ležište (21) prilagođeno za primanje okvira (1a) intrauterinog sustava, naznačen time što
2 shows the valve element 8 in a partially depressed position, namely in the intermediate position. 
Slika 2 prikazuje element ventila 8 u djelomično pritisnutom položaju, naime u međupoložaju.
the matrix and the layer sequestering the naltrexone hydrochloride in an intact dosage form. The pharmaceutical product of any of items 68-70, wherein the naltrexone hydrochloride is in an amount of from about 2 mg to about 12 mg. 
Farmaceutski proizvod prema zahtjevu 9, naznačen time da je naltrekson hidroklorid u količini od oko 2 mg do oko 12 mg, od oko 2 mg do oko 8 mg i/ili da čestice naltrekson hidroklorida sadrže više od 90%, poželjno više od 95% hidrofobnog materijala.
Examples of cyclosporine derivatives are those disclosed in W099/18120 . 
Primjeri ciklosporinskih derivata su oni objavljeni u WO99/18120.
An antibody of any one of claims 1-7 and/or a conjugate of claim 8 for use in a method of (i) inhibiting growth of a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface, (ii) killing a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface, or (iii) inhibiting metastatic spread of a cancer cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1-6 i/ili konjugat prema patentnom zahtjevu 7 za upotrebu u postupku (i) inhibicije rasta stanice raka koja eksprimira CLDN6 i koja je naznačena vezom CLDN6 s njezinom staničnom površinom, (ii) ubijanja stanice raka koja eksprimira CLDN6 i koja je naznačena vezom CLDN6 s njezinom staničnom površinom ili (iii) inhibicije metastatskog širenja stanice raka koja eksprimira CLDN6 i koja je naznačena vezom CLDN6 s njezinom staničnom površinom.
The method of item 57 or 58, wherein the TNF ligand is selected from the group consisting of: 4-1BBL, OX40L, CD70, LIGHT and CD30L. 
17. 'T-stanica prema zahtjevu 16, naznačena time da je navedeni drugi rekombinantni ko-stimulacijski ligand odabran iz skupine koju čine OX40L, CD70, LIGHT, CD30L i CD86.
A method according to claim 1, wherein the binder is selected from the group consisting of phenol formaldehyde binder, urea formaldehyde binder, phenol urea formaldehyde binder, melamine formaldehyde binder, condensation resins, acrylates and epoxy polymers. 
Metoda prema bilo kojem prethodnom zahtjevu, pri čemu se ljepilo odabire između sljedećih ljepila: fenol- formaldehidno ljepilo, karbamid-formaldehidno ljepilo, fenol-karbamid-formaldehidno ljepilo, melaminformaldehidno ljepilo, kondenzacijska smola, akrilati i ostali lateksni spojevi, epoksidni polimeri, natrijevog silikat i topljeno ljepilo od poliuretana, polietana, polietilena, polipropilena i politetrafluoretilenskih polimera.
In certain embodiments, the poly(lactic) acid-poly(ethylene)glycol copolymer used in preparing the therapeutic nanoparticle has a number average molecular weight of about 15 kDa to about 20 kDa poly(lactic acid) and a number average molecular weight of about 4 kDa to about 6 kDa poly(ethylene)glycol. 
Terapijska nanočestica u skladu s patentnim zahtjevom 1, naznačena time što sadrži otprilike 0,05 do otprilike 30 težinskih postotaka uglavnom hidrofobne kiseline; otprilike 0,2 do otprilike 25 težinskih postotaka terapijskog sredstva; i otprilike 50 do otprilike 99,75 težinskih postotaka polimera; gdje terapijska nanočestica sadrži otprilike 10 do otprilike 30 težinskih postotaka poli(etilen)glikola.
The portable machine according to claim 1, wherein said side guides of the sheet of plastic material are connected integrally to said positioning means of the roll. 
Prijenosni stroj prema zahtjevu 1, naznačen time da su spomenuti uređaji za (30,50) spojeni u jednu cjelinu sa spomenutom radnom površinom (2).
The system according to claim 1, wherein said transmitting circuitry is adapted to transmit said signal such that the characteristic signal pattern has a random or pseudo random timing. The system according to claim 1, further comprising means for 
Sustav u skladu s bilo kojim prethodnim zahtjevom, naznačen time, da navedeni krug za prijenos signala je prilagođen za prijenos navedenog signala tako da karakteristični oblik signala ima nasumičan ili pseudo nasumičan odabir vremena.
and reacting the compound of formula (B) with wherein Z and R1 are as defined in claim 1; 
i reakcija spoja formule (B) s pri čemu Z i R1 su kako je definirano u zahtjevu 1;
the proximal end of the second fragment is located within a second repeat portion; and wherein the first fragment and the second fragment are separated by less than or exactly 5 amino acids in the primary structure, wherein the polypeptide elicits antibodies that neutralise toxin A and toxin B and wherein the first repeat portion and the second repeat portion have greater than 50% sequence identity to one another. 
(iv) drugi fragment ima drugi proksimalni kraj; i gdje je prvi proksimalni kraj unutar kratkog ponavljanja i drugi proksimalni kraj je unutar kratkog ponavljanja; i gdje su prvi fragment i drugi fragment jedan uz drugog, te gdje polipeptid izaziva protutijela koja neutraliziraju toksin A i toksin B.
Monoclonal antibody of claim 1 or an antigen binding fragment thereof for use in treating a disease, disorder or condition mediated by one or more CC chemokines, wherein said disease, disorder, or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, fibrotic disease, atherosclerosis, asthma, oncogenic diseases, inflammatory bowel diseases, atopic dermatitis, psoriasis, stroke, organ transplantation, COPD, glomerulonephritis, lupus nephritis, scleroderma, cirrhosis, Alzheimer's disease, CHF-ischemia, coronary restenosis, diabetic nephrophathy/neuropathy/retinopathy, osteoarthritis, periodontitis, yeast and viral infections, and dysregulation of pregnancy. 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 1, ili njegov fragment koji veže antigen za upotrebu pri liječenju bolesti, poremećaja ili stanja uzrokovanih jednim ili više CC kemokina, naznačeno time, da je navedena bolest, poremećaj ili stanje odabrano iz skupine koja se sastoji od reumatoidnog artritisa, multiple skleroze, fibrozne bolesti, ateroskleroze, astme, onkogenih bolesti, upalne bolesti crijeva, atopičnog dermatitisa, psorijaze, moždanog udara, transplantacije organa, COPD, glomerulonefritisa, lupus nefritisa, skleroderma, ciroze, Alzheimer-ove bolesti, CHF-ishemije, koronarne restenoze, dijabetičke nefropatije / neuropatije / retinopatije, osteoartritisa, periodontitisa, infekcija uzrokovanih kvascem 1 virusima, te deregulacija trudnoće.
The nucleic acid of claim 1, wherein the amino acid sequence has at least 99% sequence identity to the amino acid sequence of SEQ ID NO:8. The nucleic acid of claim 1, wherein the amino acid residue at position 297 as in the EU index of the IgG4 Fc region is Gly. 
Fuzijski protein Fc IL-22 prema zahtjevu 1, naznačen time, da aminokiselinska sekvenca ima najmanje 96%, najmanje 97%, najmanje 98%, ili najmanje 99% identiteta sekvence prema aminokiselinskoj sekvenci odabranoj iz skupine koju čine SEQ ID NO:8 i SEQ ID NO:10.
in case said protein molecule is an antibody molecule, it has an increased Fc-mediated cellular cytotoxicity which is at least 2 times higher than the Fc-mediated cellular cytotoxicity of at least one antibody molecule composition from the same antibody molecule when expressed in the cell line ATCC No. 
- u slučaju kada je navedena molekula proteina molekula protutijela, ima povećanu staničnu citotoksičnost vezanu uz Fc, koja je najmanje 2 puta veća od stanične citotoksičnosti vezane uz Fc pripravka s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
In the present embodiment of the invention the purification of a compound of formula I, namely perindopril 
Postupak pročišćavanja spoja formule I, odnosno perindoprila COOH
adding guanidine hydrochloride to the reaction mixture from b), followed by heating; 
se dodaje gvanidin hidroklorid, nakon čega slijedi zagrijavanje, zatim
The device of claim 1, wherein each of the first layer and the one or more additional layers has a different average concentration of pharmaceutical substance. 
Uređaj prema patentnom zahtjevu 1, naznačen time, što je farmaceutska tvar prvog sloja buprenorfin.
After 2.5 hours, the reaction mixture is acidified to pH 1 with 1M HCl which leads to the formation of a precipitate. 
Nakon 2,5 sata, reakcijsku smjesu se zakiseli na pH 1 s1 MHCI, što dovodi do stvaranja taloga.
All temperatures are expressed in degrees Celsius and are uncorrected. 
Sve temperature su izražene u Celzijusovim stupnjevima i nisu korigirane.
The virus composition of any of claims 1 to 10, for use in reducing the onset of or prevent a health condition, preferably the health condition is selected from the group consisting of West Nile infection, Dengue fever, Japanese encephalitis, Kyasanur Forest disease, Murray Valley encephalitis, St. Louis encephalitis, Tick-borne encephalitis, Yellow fever and Hepatitis C Virus Infection. 
Pripravak u skladu s patentnim zahtjevom 14, naznačen time što se zdravstveno stanje bira iz skupine koju čine zaraza virusom zapadnog Nila, groznica denga, japanski encefalitis, groznica iz šume Kyasanur, australski encefalitis, St. Louis encefalitis, krpeljni encefalitis, žuta groznica i zaraza virusom hepatitisa C.
performing intra prediction on the current block using a prediction mode, indicated by the mode index, among the candidate intra prediction modes included in the candidate list. The method of claim 1, wherein the candidate intra prediction modes include at least two of a planar mode, a DC mode and a vertical mode. The method of claim 1, further comprises, when the mode prediction flag parsed from the bitstream indicates that the intra prediction modes of neighboring blocks are not used, parsing, from the bitstream, information about the intra prediction mode of the current block and performing intra prediction on the current block according to intra prediction direction which is indicated the parsed information about the intra prediction mode. 
provođenje unutrašnjeg predviđanja trenutnog bloka uz korištenje načina predviđanja, koji je određen s indeksom načina, između kandidata načina unutrašnjeg predviđanja koji su uključeni u popis kandidata, naznačen time da popis kandidata načina unutrašnjeg predviđanja sadrži ravninski način, kada su načini unutrašnjeg predviđanja lijevog bloka i gornjega bloka međusobno jednaki i unutrašnji način lijevog bloka je DC način.
dehydrating the compound of formula (22), or salt thereof, to obtain the compound according to formula (21), or tautomer, or salt thereof, 
(22) c) dehidratacija spoja formule (22) ili njegove soli, kako bi se dobio spoj u skladu sa sljedećom formulom (21) ili njegova sol:
Y is -OH, wherein X is Cl, the morpholino ring nitrogen of a further morpholino compound, the morpholino ring nitrogen of a morpholino subunit in a morpholino oligomer or a solid support; and Tr is trityl. 
Y je -OH, [image] gdje je X Cl, dušik u morfolino prstenu daljnjeg morfolino spoja, dušik u morfolino prstenu morfolino podjedinice u morfolino oligomeru ili čvrstom nosaču; i Tr je tritil.
wherein the mapping in (a) comprises identifying a plurality of biallelic polymorphism sequences; 
Postupak prema patentnom zahtjevu 1, naznačen time što mapiranje u (a) podrazumijeva identificiranje mnoštva bialelnih polimorfizama sekvenci.
removing the model or separating the model and the mold. 
- uklanjanje modela ili razdvajanje modela 1 dobivenog kalupa.
The compound for use according to claim 9 wherein the leukaemia is selected from the group comprising acute lymphoblastic leukaemia, acute myelogenous leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia, chronic lymphocytic leukaemia, monoblastic leukaemia, hairy cell leukaemia, Hodgkin lymphoma and non-Hodgkin lymphoma. 
Spoj za uporabu u skladu s patentnim zahtjevom 9, naznačeno time što je leukemija izabrana iz grupe koja sadrži akutnu limfoblastnu leukemiju, akutnu mijelogenu leukemiju, akutnu promijelocitnu leukemiju, akutnu limfocitnu leukemiju, kroničnu mijelogenu leukemiju, kroničnu limfocitnu leukemiju, monoblastnu leukemiju, leukemiju vlasastih stanica, Hodgkinov limfom i ne-Hodgkinov limfom.
or an acceptable salt, thereof; wherein: 
[image] ili njegovom prihvatljivom soli; naznačen time, da:
After 20 minutes the reaction mixture is added to a stirred solution of SO2/AcOH/CuCl2/H2O (40 ml) (the preparation of the reagent is described herein). 
Nakon 20 minuta reakcijsku smjesu se doda u miješanu otopinu 50,/AcOH/CuCLb/H20 (40 ml) (ovdje je opisana priprava reagenta).
In preferred embodiments, however, the crystalline substance is a pharmaceutically active ingredient (drug). 
Postupak prema zahtjevu 5, gdje je kristalna tvar farmaceutski djelatna tvar.
The perfusion was expressed in liters per 24 h. 
Protok je bio izražen u litrama po 24 h.
reacting the above compound of formula IIb with 2-bromo-4-fluorophenol or 2-bromo-4-fluorophenyl acetate by means of a palladium catalysed C-C coupling reaction, to obtain a compound of formula XIb in the form of diastereoisomeric mixture (R,S+S,S) 
si i y) reakciju gore navedenog spoja formule IIb sa 2-bromo-4-fluorofenolom ili 2-bromo-4-fluorofenil acetatom, pomoću reakcije C-C vezivanja katalizirane paladijem, da bi se dobio spoj formule XIb u obliku dijasteroizomerne smjese (R, S+S, S)
The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein (a) Cy2 is aryl optionally substituted by 1, 2, 3, 4, or 5 ―W'-X'-Y'-Z'; (b) wherein Cy2 is heteroaryl optionally substituted by 1, 2, 3, 4, or 5 ―W'-X'-Y'-Z'; (c) Cy2 is cycloalkyl optionally substituted by 1, 2, 3, 4, or 5 ―W'-X'-Y'-Z'; or (d) wherein Cy2 is heterocycloalkyl optionally substituted by 1, 2, 3, 4, or 5 ―W'-X'-Y'-Z'. 
Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, pri čemu (a) Cy2 je aril opcionalno zamijenjen sa 1, 2, 3, 4, ili 5 -W’-X’-Y’-Z’; (b) pri čemu Cy2 je heteroaril opcionalno zamijenjen sa 1, 2, 3, 4, ili 5 -W’-X’-Y’-Z’; (c) Cy2 je cikloalkil opcionalno zamijenjen sa 1, 2, 3, 4, ili 5 -W’-X’-Y’-Z’; ili (d) pri čemu Cy2 je heterocikloalkil opcionalno zamijenjen sa 1, 2, 3, 4, ili 5 -W’-X’-Y’-Z’.
The transmission apparatus according to claim 8, wherein the first aggregation level value is 1 or 2 and the second aggregation level value is 4 or 8. 
Naprava za prijem sukaldno jednom od zahtjeva od 5 do 7, naznačena time da je prva vrijednost razine agregacije 21 da je druga vrijednost razine agregacije 4 ili 6.